Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

Title
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
Authors
Keywords
Chronic myeloproliferative disorders, JAK inhibitor, Polycythemia vera, Ruxolitinib
Journal
ANNALS OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-05-27
DOI
10.1007/s00277-018-3365-y

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now